| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. International clinical psychopharmacology. vol 33. issue 3. 2019-02-25. PMID:29406406. |
two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. |
2019-02-25 |
2023-08-13 |
Not clear |
| Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aok. Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study. International clinical psychopharmacology. vol 33. issue 3. 2019-02-25. PMID:29406406. |
this study aimed to assess the comparative effectiveness of risperidone (ris) versus aripiprazole (arp) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment. |
2019-02-25 |
2023-08-13 |
Not clear |
| Robert J Feeley, Bachaar Arnaout, Gihyun Yoo. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal of clinical psychopharmacology. vol 37. issue 6. 2019-01-07. PMID:29028689. |
effective switch from clozapine to aripiprazole in treatment-resistant schizophrenia and comorbid alcohol use disorder. |
2019-01-07 |
2023-08-13 |
Not clear |
| Leslie Citrom. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert review of neurotherapeutics. vol 17. issue 10. 2019-01-03. PMID:28832262. |
approved indications have expanded beyond schizophrenia to also include bipolar maintenance (risperidone microspheres and aripiprazole monohydrate) and schizoaffective disorder (paliperidone palmitate monthly). |
2019-01-03 |
2023-08-13 |
Not clear |
| Esther Letícia Amorim Ribeiro, Tácio de Mendonça Lima, Marcio Eduardo Bergamini Vieira, Sílvia Storpirtis, Patricia Melo Aguia. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. European journal of clinical pharmacology. vol 74. issue 10. 2018-12-19. PMID:29905899. |
efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. |
2018-12-19 |
2023-08-13 |
Not clear |
| Esther Letícia Amorim Ribeiro, Tácio de Mendonça Lima, Marcio Eduardo Bergamini Vieira, Sílvia Storpirtis, Patricia Melo Aguia. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. European journal of clinical pharmacology. vol 74. issue 10. 2018-12-19. PMID:29905899. |
to conduct an overview to summarize the efficacy and safety of aripiprazole for the treatment of schizophrenia. |
2018-12-19 |
2023-08-13 |
Not clear |
| Sulgi Yoo, Mi-Yeon Kim, Jae Youl Ch. Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic. Biochemical pharmacology. vol 148. 2018-12-17. PMID:29241811. |
aripiprazole (arp) is a partial agonist of dopamine d2 receptors that is commonly prescribed to treat schizophrenia and bipolar disorder. |
2018-12-17 |
2023-08-13 |
Not clear |
| Sangho Shin, Seoyoung Kim, Seongho Seo, Jae Sung Lee, Oliver D Howes, Euitae Kim, Jun Soo Kwo. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [ Translational psychiatry. vol 8. issue 1. 2018-12-11. PMID:29686254. |
the relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [ aripiprazole's effects on cognitive function in patients with schizophrenia are unclear because of the difficulty in disentangling specific effects on cognitive function from secondary effects due to the improvement in other schizophrenic symptoms. |
2018-12-11 |
2023-08-13 |
Not clear |
| Sangho Shin, Seoyoung Kim, Seongho Seo, Jae Sung Lee, Oliver D Howes, Euitae Kim, Jun Soo Kwo. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [ Translational psychiatry. vol 8. issue 1. 2018-12-11. PMID:29686254. |
this study aims to investigate aripiprazole's effect on working memory by determining the correlation between dopamine d2/3 (d2/3) receptor occupancy and working memory of patients with schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Hideo Matsumoto, Jun Ishigooka, Hiroaki Ono, Yoshihiro Tador. Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. Psychiatry and clinical neurosciences. vol 72. issue 9. 2018-12-11. PMID:29774635. |
safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in japan. |
2018-12-11 |
2023-08-13 |
Not clear |
| Hideo Matsumoto, Jun Ishigooka, Hiroaki Ono, Yoshihiro Tador. Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. Psychiatry and clinical neurosciences. vol 72. issue 9. 2018-12-11. PMID:29774635. |
the purpose of this study was to evaluate the safety and efficacy of aripiprazole in adolescents with schizophrenia (scz) in japan. |
2018-12-11 |
2023-08-13 |
Not clear |
| Marjie L Hard, Angela Y Wehr, Yangchun Du, Peter J Weiden, David Walling, Lisa von Moltk. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia. Journal of clinical psychopharmacology. vol 38. issue 5. 2018-12-11. PMID:30015676. |
pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Giordano D'Urso, Annalisa Anastasia, Elena Toscano, Sara Patti, Andrea de Bartolomei. Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors. Experimental and clinical psychopharmacology. vol 26. issue 5. 2018-12-11. PMID:30035575. |
here we present the case of a 43-year-old caucasian man with schizophrenia who developed atrial fibrillation (af) after starting aripiprazole treatment. |
2018-12-11 |
2023-08-13 |
Not clear |
| Zofia Rogóż, Agnieszka Wąsik, Elzbieta Lorenc-Koc. Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. Pharmacological reports : PR. vol 70. issue 4. 2018-11-19. PMID:29885435. |
thus, in the present study, we aimed to evaluate the effect of ads, escitalopram (esc) or mirtazapine (mir) and aripiprazole (an atypical antipsychotic drug) given separately or jointly, on the mk-801-induced positive and cognitive symptoms of schizophrenia in mice. |
2018-11-19 |
2023-08-13 |
mouse |
| Dieter Naber, Ross A Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze, Steven G Potki. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophrenia research. vol 192. 2018-10-31. PMID:28433498. |
long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the qualify extension study. |
2018-10-31 |
2023-08-13 |
Not clear |
| Dieter Naber, Ross A Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze, Steven G Potki. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophrenia research. vol 192. 2018-10-31. PMID:28433498. |
to evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400mg (aom 400) in patients with schizophrenia. |
2018-10-31 |
2023-08-13 |
Not clear |
| Xiao-Jia Jiang, Fu-Xi Wu, Jian-Ping Zhang, Lei Shi, Jin-Qing Hu, Hai-Zhen Zhu, Bing Xiao, Wei-Cheng Lin, Yu-Guan Wen, De-Wei Shan. Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Drug research. vol 68. issue 7. 2018-10-18. PMID:29482256. |
effects of risperidone and aripiprazole on serum levels of prolactin, testosterone and estradiol in female patients with schizophrenia. |
2018-10-18 |
2023-08-13 |
Not clear |
| Xiao-Jia Jiang, Fu-Xi Wu, Jian-Ping Zhang, Lei Shi, Jin-Qing Hu, Hai-Zhen Zhu, Bing Xiao, Wei-Cheng Lin, Yu-Guan Wen, De-Wei Shan. Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Drug research. vol 68. issue 7. 2018-10-18. PMID:29482256. |
to evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in china. |
2018-10-18 |
2023-08-13 |
Not clear |
| Megan J Ehret, Erica Davis, Sarah E Luttrell, Caroline Clar. Aripiprazole Lauroxil NanoCrystal Clinical schizophrenia & related psychoses. vol 12. issue 2. 2018-10-16. PMID:30040476. |
aripiprazole lauroxil nanocrystal nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. |
2018-10-16 |
2023-08-13 |
Not clear |
| Li-Juan Gao, Hua-Gui Guo, Zhen-Tao Liang, Xiao-Xiao Zhong, Jin-Cai Zhu, Yu Yan. [Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. Zhonghua nan ke xue = National journal of andrology. vol 23. issue 7. 2018-10-12. PMID:29723454. |
to investigate the clinical effects of aripiprazole on sexual dysfunction induced by amisulpride or risperidone in male patients with schizophrenia. |
2018-10-12 |
2023-08-13 |
Not clear |